Close

Credit Suisse Thoughts on Gilead Sciences (GILD) / Merck (MRK) Partnership

March 16, 2021 8:51 AM EDT Send to a Friend
Credit Suisse analyst Evan Seigerman reiterated a Neutral rating and $65.00 price target on Gilead Sciences (NASDAQ: GILD) after the ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE

Member Login